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Abstract
Tumor relapse after chemotherapy-induced regression is a
major clinical problem, because it often involves inoperable
metastatic disease. Tumor-associated macrophages (TAM) are
known to limit the cytotoxic effects of chemotherapy inpreclinical
models of cancer. Here, we report that an alternatively activated
(M2) subpopulation of TAMs (MRC1þTIE2HiCXCR4Hi) accumu-
late around blood vessels in tumors after chemotherapy, where
they promote tumor revascularization and relapse, in part, via
VEGF-A release. A similar perivascular, M2-related TAM subset
was present in human breast carcinomas and bone metastases
after chemotherapy. Although a small proportion of M2 TAMs
were also present in hypoxic tumor areas, when we genetically
ablated their ability to respond to hypoxia via hypoxia-inducible
factors 1 and 2, tumor relapse was unaffected. TAMs were the
predominant cells expressing immunoreactive CXCR4 in chemo-
therapy-treated mouse tumors, with the highest levels expressed
by MRC1þ TAMs clustering around the tumor vasculature. Fur-
thermore, the primary CXCR4 ligand, CXCL12, was upregulated
in these perivascular sites after chemotherapy, where it was
selectively chemotactic for MRC1þ TAMs. Interestingly, HMOX-
1, a marker of oxidative stress, was also upregulated in perivas-
cular areas after chemotherapy. This enzyme generates carbon
monoxide from the breakdown of heme, a gas known to upre-
gulate CXCL12. Finally, pharmacologic blockade of CXCR4 selec-
tively reduced M2-related TAMs after chemotherapy, especially
those in direct contact with blood vessels, thereby reducing tumor
revascularization and regrowth. Our studies rationalize a strategy
to leverage chemotherapeutic efﬁcacy by selectively targeting this
perivascular, relapse-promoting M2-related TAM cell population.
Cancer Res; 75(17); 3479–91. 2015 AACR.
Introduction
The regrowth of tumors after treatment with cytotoxic agents
poses a major threat to survival in cancer patients, particularly
those with inoperable primary and/or metastatic tumors as they
often rely heavily on chemotherapy to slow tumor growth and
reduce its burden. The development of resistance results in poor
survival rates for patientswith, for example, inoperable pancreatic
or lung cancer, who often survive for less than 12 months after
diagnosis (1, 2).New therapeutic strategies are, therefore, urgently
needed to delay or prevent tumor regrowth after early cycles of
chemotherapy as these would extend life.
Malignant tumors contain various CD11bþ myeloid cells,
including granulocytes, myeloid-derived suppressor cells
(MDSC), and tumor-associated macrophages (TAM; ref. 3). The
latter are recruited asmonocytes from theperipheral blood,which
are themselves derived from progenitor cells in the bone marrow
(4, 5). After entry into tumors, monocytes differentiate into
macrophages (6) and promote tumor progression by stimulating
tumor invasion, neovascularization and metastasis, and suppres-
sing antitumor immunity (5, 7). TAMs express a broad spectrum
of activation states between the two extreme forms of "classical"
(M1) and "alternative"' (M2) activation, with a tendency toward
the latter (8). M2-skewed TAMs are characterized by their upre-
gulation of various receptors, including the mannose receptor
C-type lectin (MRC1/CD206) and the angiopoietin receptor, TIE2
(9). Indeed, TAMs expressing high levels of these two receptors
have been shown to play an essential role in promoting angio-
genesis in untreated mouse tumors (10).
A variety of anticancer therapies have been shown to stimulate
the recruitment of CD11bþ myeloid cells by mouse tumors
(11, 12). For example, TAMs accumulate in mouse tumors after
chemotherapy (13–15), ionizing radiation (16–18), and the
vascular disrupting agent combretastatin-A4-P (CA-4-P; ref. 19).
1Department of Oncology, University of Shefﬁeld Medical School,
Shefﬁeld, United Kingdom. 2MRC Centre for Reproductive Health,
Queen's Medical Research Institute, University of Edinburgh, Edin-
burgh, Scotland, United Kingdom. 3Swiss Institute for Experimental
Cancer Research (ISREC), School of Life Sciences, Ecole Polytechni-
que Federale de Lausanne (EPFL), Lausanne, Switzerland. 4Cancer
Biology and Genetics Program, Memorial Sloan Kettering Cancer
Center, New York, New York. 5Cancer Therapeutics Program, Ottawa
HospitalResearch Institute, andDepartmentofMedicine,Universityof
Ottawa,Ontario, Canada. 6Breast Medical Oncology,The University of
Texas MD Anderson Cancer Center, Houston, Texas. 7Department of
Developmental and Molecular Biology, Albert Einstein College of
Medicine, New York, New York.
Note: Supplementary data for this article are available at Cancer Research
Online (http://cancerres.aacrjournals.org/).
R. Hughes and B.-Z. Qian share ﬁrst authorship of this article.
J.W. Pollard and C.E. Lewis share senior authorship of this article.
Corresponding Author: Claire E. Lewis, University of Shefﬁeld Medical School,
Beech Hill Road, Shefﬁeld, Yorkshire S10 2RX, United Kingdom. Phone/Fax: 44-
114-271-2903; E-mail: claire.lewis@shefﬁeld.ac.uk
doi: 10.1158/0008-5472.CAN-14-3587
2015 American Association for Cancer Research.
Cancer
Research
www.aacrjournals.org 3479
on September 1, 2015. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 12, 2015; DOI: 10.1158/0008-5472.CAN-14-3587 
Importantly, the mononuclear phagocyte growth factor CSF1
(13) and chemokines CCL2 (14) and CXCL12 (16, 19) are
increased in tumors after such anticancer therapies, and can trigger
monocyte recruitment (4, 5). These cells then reduce the efﬁcacy
of chemotherapy by limiting vascular permeability via their
expression of MMP9 (14), promoting resistance to therapy-
induced death via their expression of cathepsin serine proteases
(15) and by suppressing the recruitment/activation of cytotoxic
T cells (12, 13).
Considerable evidence has emerged recently for M2-activat-
ed macrophages playing an important role in repair and
remodeling after tissue injury. For example, they are promi-
nent in diseased tissues in spinal cord injury, myocardial
infarction, and various forms of renal disease, (20). Further-
more, TAMs with similar phenotypes have been implicated in
tumor relapse after therapies like irradiation and CA-4-P
(17, 19). Although MRC1þ TAMs are increased in MMTV-
PyMT mammary tumors after doxorubicin treatment (14), the
role of M2 TAMs in tumor relapse after chemotherapy has not
been deﬁned.
Our studies show that MRC1þ TAMs are elevated in mouse
tumors after treatment with various chemotherapeutic agents.
Moreover, this TAM subset was further deﬁned as MRC1Hi
TIE2HiCXCR4HiVEGFAþ and shown to accumulate preferentially
in vascularized, CXCL12-rich regions of tumors after chemother-
apy. Blockade ofCXCR4 signaling prevented this close association
with the tumor vasculature after chemotherapy, resulting in a
marked delay in subsequent tumor revascularization and relapse.
These ﬁndings suggest that selective targeting of vessel-associated,
M2-skewed TAMs after chemotherapy could increase the relapse-
free survival of cancer patients.
Materials and Methods
Mouse studies
To investigate the mechanisms regulating tumor relapse
after chemotherapy, we primarily used the Lewis lung carci-
noma model (21) and the MMTV-PyMT model of breast cancer
(15). These syngeneic tumor models respond to chemotherapy
with an initial phase of tumor growth inhibition, followed by
a distinct regrowth phase. Transgenic tumor models were
not considered suitable as their responses to some cytotoxic
agents can be so minimal that a relapse phase is not evident
(13, 22). Furthermore, tumors in these models are often
multifocal making the kinetics of tumor relapse difﬁcult to
assess accurately.
Our mouse studies were conducted in accordance with either
UK Home Ofﬁce regulations (C.E. Lewis/M. Muthana/R.
Hughes), the Veterinary Authorities of the Canton Vaud (M. De
Palma), the institutional standards of the Research Animals
Resource Centre at Memorial Sloan Kettering Cancer Centre
(J.A. Joyce; New York, NY), and the Albert Einstein College of
Medicine Animal Use Committee (J.W. Pollard). LLC1/cyclo-
phosphamide studies using 8-week-old C57BL/6 mice were per-
formed asdescribed previously (21). For LLC1/AMD3100 studies,
AMD3100 was given concurrently (10 mg/kg) with cyclophos-
phamide, i.p. every day for 7 days. Tumors and organs were
harvested at the indicated times. Mice were treated i.p. with
pimonidazole (60 mg/kg) and bromodeoxyuridine (BrdUrd;
100 mg/kg) 2 hours before sacriﬁce to label hypoxia and prolif-
erating cells, respectively.
4T1/paclitaxel studies
Female Balb/c mice (>8 weeks) were orthotopically implanted
with 1  106 4T1 murine mammary adenocarcinoma cells.
Tumors were grown for 10 days before mice were injected i.p.
with either cremaphore or cremophore þ paclitaxel (10 mg/kg)
every 5 days for a total of three doses, themice were sacriﬁced and
tissues harvested 4 days after the last treatment. Orthotopic
MMTV-PyMT/doxorubicin studies were performed as previously
described (15). Mice bearing implanted tumors were injected i.v.
with a single dose of doxorubicin (5 mg/kg) when at 250 mm3
and sacriﬁced 7 days after therapy.
Monocyte/macrophage-speciﬁc ablation of Vegfa studies
Female Tg(Csf1r-Mer-iCre-Mer)1jwp;Vegfa
ﬂ/ﬂ) mice (>8 weeks),
shown to speciﬁcally lack the expression of VEGFA in the mono-
cyte/macrophage lineage after treatment with tamoxifen (23), or
Cre-negative litter mates (ages 8 weeksþ), were orthotopically
implantedwith the syngeneicMMTV-PyMT cell line F246-6. Vegfa
ﬂoxedmicewere the kind gift ofDr.Naploeone Ferrar,Genentech.
Mice with established tumors were treated with a single i.v.
injection of either vehicle (PBS) or doxorubicin (5 mg/kg) and
24 hours later with tamoxifen via their food (3 mg/20 g body
weight/day). Treatment with tamoxifen was then maintained
throughout tumor regrowth. Tumor growth was monitored by
calipermeasurements. In the LLC1/TAMadoptive transfer studies,
C57BL/6 mice implanted with LLCs and treated with cyclophos-
phamide as outline above, 48 hours after the last dose of cyclo-
phosphamide, donormice were sacriﬁced, their tumors removed,
enzymatically dissociated, and MRC1Hi and MRC1Lo TAMs were
puriﬁed by ﬂow cytometry. Recipient mice were randomized into
three groups and received either 50103MRC1Hi TAMs, 50103
MRC1Lo TAMs, or saline via a 25 mL intratumoral injection. After
injection of these cells or saline, tumor regrowth was then
monitored.
Human breast carcinomas and metastatic bone lesions
Four patients with newly diagnosed breast cancer underwent
neoadjuvant chemotherapy as previously described (24). Resid-
ual tumor tissues were collected at the time of surgery (which took
place 21–28days after the last dose of paclitaxel). Biopsies of bone
metastatic lesions were also obtained from ﬁve advanced breast
cancer patients. All biopsies were obtained under informed con-
sent following procedures approved by the Ottawa Health
Sciences Research Ethics Board. Samples were collected as previ-
ously described (25). All biopsies were taken within 6 to 15 days
of treatment with either chemotherapy alone (paclitaxel, doce-
taxel, or 5-ﬂuoruracil/doxorubicin/cyclophosphamide) or with-
out pamidronate.
Immunoﬂuorescence and IHC studies
Frozen tumor sections were blocked with 1% BSA and 5% goat
serum for 30 minutes and incubated with various primary anti-
bodies (Supplementary Table S1), for 1 hour at room tempera-
ture. Alexa ﬂuor–conjugated anti-rabbit or anti-rat secondary
antibodies were used with unconjugated primary antibodies. For
BrdUrd staining, DNA in frozen tissue sections was denatured
with 2NHCl for 15minutes before immunostaining, as described
above. Nuclei in all tumor sections were counterstained with
DAPI. Formalin-ﬁxed, parafﬁn-embedded tissues were rehy-
drated, peroxidase blocked, then antigen retrieved, serum
blocked, and incubated with primary antibodies for 1 to 2 hours.
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Primary antibodies were detected with appropriate ABC or Poly-
mer detection kits followed by chromagen staining with DAB.
DistributionofMRC1þTAMs relative tobloodvessels inhuman
primary breast tumors
Thenumber ofMRC1þTAMspresentwithin a250-mmradius of
a given blood vessel was counted in six randomly selected areas
per tumor section. Then,within this 250mmradius, thedistance of
each MRC1þ TAM was measured to the nearest vessel and the
number of MRC1þ TAMs within or beyond 150 mm from that
vessel was expressed as a%MRC1þ TAMs within the region being
analyzed. These were deﬁned as "perivascular" or "avascular"
MRC1þ TAM subsets, respectively.
Tumor dissociation/ﬂow-cytometric studies
Tumors were enzymatically dissociated and labeled with anti-
bodies as described previously (9). All antibody incubations were
performed for 1hour at 4C.Cell staining analyses and cell sorting
experiments were performed using BD LSRII and BD FACSAria,
respectively.
VEGFA ELISA studies
CD45þCD11bþLy6GF4/80þ TAMs were isolated from three
pooled, dissociated control, and cyclophosphamide-treated LLC1
tumors.Onehundred thousand sorted cellswere seeded in100mL
of medium and cultured overnight. Conditioned medium was
examined for VEFGA release using a mouse VEGFA Quantikine
Sandwich ELISA (R&D Systems).
Chemotaxis assay
MRC1þ/Hi (CD11bþLy6G_F4/80þMRC1Hi) and MRC1/Lo
(CD11bþLy6G_F4/80þMRC1Hi) TAMs were FACSorted from dis-
sociated cyclophosphamide-treated LLC1 tumors and seeded into
Transwell inserts (4mmpores, VWR International), 50 103 cell per
well. Lower chambers contained either medium alone, medium
supplemented with 10 nmol/L BSA or 10 nmol/L recombinant
murine CXCL12 (100 ng/mL). After an incubation of 6 hours at
37C, the chambersweredissassembledand themembranes stained
with crystal violet. The upper surface of each Transwell insert was
scraped to remove non-migrated cells before quantiﬁcation.
Quantiﬁcation of spontaneous LLC1 lung metastases
Sections (4 mm thick) were cut from formalin-ﬁxed, parafﬁn-
embedded lungs and stainedwith haemotoxylin and eosin. These
stained sectionswere imaged using the Aperio slide scanner (Leica
Biosystems), and the number of metastases per section and total
metastatic area quantiﬁed using ImageScope analysis software
(Leica Biosystems).
Statistical analysis
All data representmean values SEM.P values of less than 0.05
were considered to be signiﬁcant. All statistical comparisons were
made using the nonparametric Mann–Whitney U test (paired or
unpaired as appropriate).
Results
M2-skewed (MRC1þTIE2HIVEGFAþ) TAMs are abundant in
mouse tumors after chemotherapy and promote their relapse
Three i.p. injections of the cytotoxic agent, cyclophosphamide,
resulted in the complete cessation of LLC1 tumor growth, fol-
lowedby regrowthbeginning 7days after treatment stops (Fig. 1A,
left). Forty-eight hours after the last cyclophosphamide injection
(day 6), LLC1s contained signiﬁcantly (P < 0.05) shorter blood
vessels and more hypoxia than size-matched controls (Supple-
mentary Fig. S1A). Consistent with earlier observations for
MMTV-PyMT implants treated with paclitaxel (13), TAMs were
enriched among those leukocytes present in LLC1s 48 hours after
cyclophosphamide (Supplementary Fig. S1B). In addition,
there was a signiﬁcant (P < 0.05) increase in the overall number
of F4/80þ TAMs in cyclophosphamide-treated LLCs compared
with size-matched controls. This was also seen in paclitaxel-
treated, orthotopic 4T1 tumors, and doxorubicin-treated ortho-
topic MMTV-PyMT implants (Supplementary Fig. S1C).
Cyclophosphamide treatment of LLC1s resulted in a signiﬁcant
(P < 0.05) increase in the number of F4/80þ TAMs expressing the
M2-marker, MRC1, relative to size-matched controls. In contrast,
there was a signiﬁcant (P < 0.05) drop in F4/80þ/MRC1 TAMs
after cyclophosphamide (Fig. 1A, right). Also, TAMs from cyclo-
phosphamide-treated LLC1s expressed higher surface MRC1 than
those from size-matched controls (Fig. 1B). Consistent with
previous ﬁndings in untreated mouse tumors (9, 10), MRC1Hi
TAMs in cyclophosphamide-treated LLC1s coexpressed elevated
TIE2 (Fig. 1C and D). A similar increase inMRC1þ TAMs was also
seen in orthotopic 4T1 andMMTV-PyMT implants after paclitaxel
and doxorubicin, respectively (Supplementary Fig. S1D). In all
threemodels, the vastmajority ofMRC1þ cells F4/80þ TAMs, and
the small number of F4/80MRC1þ (presumably dendritic) cells
were not signiﬁcantly increased after treatment with cyclophos-
phamide, paclitaxel, or doxorubicin (Supplementary Fig. S2A).
BrdUrd uptake was negligible in MRC1þ TAMs in both size-
matched control and cyclophosphamide-treated LLC1 tumors,
indicating their nonproliferative status (Supplementary Fig. S2B).
As chemotherapy-induced changes in circulating hematopoietic
stem andprogenitor cells (HS/PCs) could, in theory, contribute to
the increase of TAM numbers after therapy, we also performed
dual immunoﬂuorescence labeling for HS/PC markers, c-Kit and
Sca1. Although c-KitþSca1þ cells were detected in the spleens of
LLC1 tumor-bearing mice (positive control for the staining), no
such cells were detected in either control or cyclophosphamide-
treated LLC1s (Supplementary Fig. S2C). These data indicate
that the chemotherapy-induced increase in TAMs is most likely
to be due to increased monocyte recruitment rather than the
proliferation of existing TAMs or their differentiation from
recruited HS/PCs.
We then isolated F4/80þMRC1þ/Hi and F4/80þMRC1/Lo
TAMs from cyclophosphamide-treated LLC1 tumors by FACS and
injected them into cyclophosphamide-treated LLC1 tumors in
littermates (Fig. 2A). MRC1þ/Hi TAMs, but not MRC1/Lo TAMs
from treated tumors or TAMs from vehicle-treated tumors, accel-
erated tumor regrowth after cyclophosphamide. This was accom-
panied by a signiﬁcant (P < 0.05) increase in the number of
MRC1þ TAMs, CD31þ blood vessels, and a moderate increase in
BrdUrdþ (proliferating) cells in cyclophosphamide-treated LLC1s
receiving MRC1þ/Hi TAMs. Very few (< 1%) of CD45þ leukocytes
contained immunodetectable BrdUrd (Fig. 2B–E).
MRC1þ TAMs are proangiogenic in untreated tumors and
express the important proangiogenic mediator VEGFA (9, 26).
Moreover, myeloid-speciﬁc deletion of VEGFA is known to have
profound effects on the vascularization and progression of
untreated mouse tumors (27). We, therefore, investigated the
role of VEGFA derived from MRC1þ TAMs in tumor-relapse after
Macrophages and Tumor Relapse
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chemotherapy. As reported previously in mouse tumors (25),
VEGFA was expressed by both TAMs and other (F4/80) cells in
control LLC1s (Fig. 3A and Supplementary Fig. S3A). However,
within 48hours of the last dose of cyclophosphamide, VEGFAwas
expressed almost exclusively by MRC1þ TAMs (Supplementary
Fig. S3B). As the expression of VEGFA was closely associated with
MRC1þ TAMs, and because the latter were more abundant in
cyclophosphamide-treated LLCs (Fig. 3B and C), we postulated
that the macrophage population as a whole found within cyclo-
phosphamide-treated LLCsmight be capable of producing higher
levels of VEGFA. Indeed, the release of VEGFA was found to be
signiﬁcantly greater for TAMs sampled from cyclophosphamide-
treated LLCs (Fig. 3D).
MDSCs (CD11bþGr1þ) in tumor-bearing mice are also
reported to express MRC1 raising the possibility that some
VEGFA-expressing MRC1þ cells in cyclophosphamide-treated
tumors might have been MDSCs (28). However, we found that
both granulocytic (CD45þCD11bþLy6Gþ) and monocytic
(CD45þCD11bþLy6GLy6Cþ) MDSC subsets were depleted
in cyclophosphamide-treated tumors, and that the expression
of MRC1 on monocytic MDSCs was signiﬁcantly (P < 0.05)
lower than that on TAMs (Supplementary Fig. S3C). Taken
together, these data suggest that MDSCs are unlikely to repre-
sent a signiﬁcant proportion of the MRC1Hi cells in our LLC1
tumors.
We previously showed that a subset of TAMs accumulates in
hypoxic areas of untreatedmouse and human tumors (29), where
they respond to hypoxia by upregulating hypoxia-inducible fac-
tors (HIF) 1 and 2 and a wide array of HIF-dependent M2 genes
(30). As we detected some MRC1þ TAMs in the hypoxic regions
of cyclophosphamide-treated LLC1 tumors (Supplementary
Fig. S4A), albeit at much lower numbers than in the well-vascu-
larized, normoxic (PIMO) regions (Fig. 4A), we investigated the
possibility that hypoxia-regulated transcriptional programming
Figure 1.
Effects of cyclophosphamide (CTX) on
tumor growth and accumulation of M2
TAMs in LLC1 tumors. A and B, growth
kinetics of LLC1s after three i.p.
injections with either 150 mg/kg
cyclophosphamide or PBS (left; A), the
number of MRC1þ or MRC1 F4/80þ
TAMs (right; n ¼ 7–8/group), and their
cell-surface expression of MRC1 (B), as
detected by ﬂow cytometry (n ¼ 5–6/
group), 2 days after the last dose of
cyclophosphamide (day 6, i.e., before
the regrowth phase). C, ﬂow-cytometric
analysis of TIE2 and MRC1 on TAMs from
cyclophosphamide-treated tumors.
D, colocalization of MRC1 and TIE2 on
TAMs in cyclophosphamide-treated
tumors (see yellow arrows and inset for
dual-stained cells). V, vessel. Bars,
50 mm.  , P < 0.05.
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(via HIFs 1 and 2) might contribute to the relapse-promoting
functions of TAMs. LLC1s were implanted into LysMCre/þHIF1ﬂ/ﬂ
or LysMcre/þHIF2ﬂ/ﬂ myeloid-speciﬁc knockout mice and treated
with vehicle or cyclophosphamide. HIF knockout was seen to
have no effect on the number of MRC1þ TAMs in either the
hypoxic or PIMO areas in cyclophosphamide-treated LLC1s, or
on tumor relapse (Supplementary Fig. S4B and S4C). IHC staining
demonstrated a reduction of >90% in TAMs expressing HIF1a or
2a in control LLC1s, conﬁrming high efﬁciency of LysCre-targeted
HIF allele ablation in our mice (Supplementary Fig. S4D). These
data suggest that hypoxia and HIF1/2-regulated transcriptional
programming do not regulate the relapse-promoting functions of
MRC1þ TAMs.
MRC1þ TAMs accumulate in well-vascularized areas of tumors
after chemotherapy in both mouse and human tumors and
promote tumor relapse: role of VEGFA
Previous studies have shown thatMRC1þTAMs can reside close
to blood vessels in untreated mouse tumors (10). Furthermore,
the aforementioned HIF knockout study demonstrated an
increase in MRC1þ TAMs in PIMO vascularized areas (PIMO
VA) in cyclophosphamide-treated tumors (Supplementary
Fig. S4B). We, therefore, conducted a more detailed immunoﬂu-
orescence staining analysis of the distribution of these cells in
control and cyclophosphamide-treated LLC1s. This showed that,
although MRC1þ TAMs were evenly distributed between PIMO
VA and PIMOþ hypoxic areas in size-matched control tumors,
Figure 2.
Effects of adoptive transfer of MRC1Hi
vs MRC1Lo TAMs on LLC1 relapse after
cyclophosphamide (CTX). A, design
schematic of the TAM transfer
experiment. B, quantiﬁcation of
MRC1þ TAMs in tumors receiving
adoptive transfer of MRC1/Lo or
MRC1þ/Hi TAMs. C, LLC1 regrowth
after the last cyclophosphamide
injection (day 0). D and E,
vascularization (D) and proliferation
(E) in LLC1 tumors receiving MRC1Hi
or MRC1Lo (n ¼ 5/group). Costaining
of cyclophosphamide-treated LLC1
tumor sections with antibodies
against the pan-leukocyte marker
(CD45) and BrdUrd. Fewer than 1%
of proliferating cells were leukocytes
in either group.  , P < 0.05. Bars,
50 mm.
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there was a signiﬁcant (P < 0.05) increase in the number of F4/
80þMRC1þ TAMs in the former in cyclophosphamide-treated
LLC1s (Fig. 4A). As cyclophosphamide treatment also resulted
in reduced tumor vascularity (Supplementary Fig. S1A), we nor-
malized MRC1þ TAM numbers to CD31þ area in PIMO VA of
control and cyclophosphamide-treated LLC1s. Interestingly, this
showed that the increase in MRC1þ TAMs in PIMO VA is
independent of changes in the vasculature (Fig. 4A, far right).
Further immunoﬂuorescent analysis of 4T1 and PyMT-MMTV
tumors demonstrated a similar increase in the number of
vessel-associated MRC1þ TAMs after treatment with paclitaxel
and doxorubicin, respectively (Fig. 4B). Furthermore, because
the majority of MRC1þ TAMs coexpressed VEGFA in both
control and cyclophosphamide-treated LLCs, this meant that
there was also a signiﬁcant increase in VEGFAþ TAMs in
perivascular areas (Fig. 4C, top). Interestingly, there was also
Figure 3.
Effect of cyclophosphamide (CTX) on
the number of MRC1þ VEGFAþ TAMs
in LLC1 tumors and VEGFA release by
TAMs in vitro. A, representative
immunostaining for F4/80þ, MRC1þ,
and VEGFAþ. VEGF-expressing
F4/80 cells (yellow arrows) and
F4/80þ TAMs (orange arrows). B,
VEGFA colocalization with MRC1 in
TAMs. Bar, 50 mm. C, number of
MRC1þ VEGFAþ TAMs. D, VEGFA
release by CD45þCD11bþLy6GF4/
80þ TAMs (VEGFA release in medium
over 16 hours, standardized by live
TAM numbers).  , P < 0.05.
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a signiﬁcant (P < 0.05) increase in the number of MRC1þ
VEGFAþ TAMs in direct contact with the abluminal surface of
the tumor vasculature in cyclophosphamide-treated tumors
(Fig. 4C, bottom). However, the preferential accumulation of
MRC1þVEGFAþ TAMs in the PIMO_VA regions of chemother-
apy-treated tumors was no longer present after relapse, suggest-
ing that the accumulation of MRC1þ TAMs was an acute,
transient response to therapy (Supplementary Fig. S5A).
MRC1þ TAMs were also seen to preferentially localize in
perivascular areas (i.e., within 150 mm of blood vessels) in
human breast carcinomas 21 to 28 days after three cycles of
neoadjuvant paclitaxel (Fig. 4D, left and middle), and in breast
cancer metastases in the bone after chemotherapy (with or
without bisphosphonates; Fig. 4D, right).
Immunoﬂuorescence staining of VEGFA in orthotopic MMTV-
PyMT tumors excised at day 6 indicated that only MRC1þ, not
MRC1, TAMs expresseddetectable levels of VEGFA in vehicle and
doxorubicin-injected Cre tumors. Indeed, >98% of vessel-asso-
ciated MRC1þ TAMs were VEGFAþ in both groups of tumors
(Fig. 5A and B). So, we investigated the role of VEGFA expression
by these MRC1þ TAMs in tumor relapse using the Csf1r-Mer-iCre-
Mer inducible cre-recombinase/estrogen receptor fusion protein
Figure 4.
Effect of cytotoxic drugs on the
distribution of MRC1þ TAMs in mouse
and human tumors: colocalization
with VEGFA. A, immunostaining of
MRC1þ TAMs in PIMOVA and
hypoxic (PIMOþ) areas of LLC1 tumors
48 hours after last injection of
cyclophosphamide (CTX; left and
middle), and their abundance in
PIMO VA areas normalized by CD31þ
area (right; n ¼ 4/group). B, MRC1þ
TAM accumulation in vessel-
associated (VA) areas in 4T1
(n ¼ 8–9/group) and MMTV-PyMT
tumor implants after treatment with
paclitaxel (PTX) or doxorubicin (DOX)
respectively (n ¼ 7/group). C, overall
number of MRC1þVEGFAþ TAMs in
PIMO VA (top) and the number in
direct contact with CD31þ vessels
(abluminal; bottom) in control and
cyclophosphamide-treated LLCs 48
hours after the ﬁnal dose of
cyclophosphamide (both normalized
by total CD31þ area). D, MRC1þ TAMs
in vascular or avascular areas of
human primary carcinomas 3 weeks
after three cycles of paclitaxel
treatment (black arrows; n ¼ 4
biopsies). MRC1þ macrophages near
vessels in bone metastases from
patients with advanced breast cancer
after treatment (red arrows; n ¼ 4
biopsies). Bars, 50 mm.  , P < 0.05.
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model for the tamoxifen-induced ablation of VEGFA selectively in
monocytes/macrophages (23).
Female Csf1r-Mer-iCre-Mer FVB/n mice were orthotopically
implantedwith syngeneicMMTV-PyMT tumors and administered
tamoxifen 24 hours after a single injection of either vehicle or
doxorubicin. In addition, tamoxifen was given continuously
thereafter to ensure VEGFA knockout until mice were sacriﬁced
at the end of the experiment (day 14), with the same treatment
given to control Cre-recombinase negative mice (Fig. 5C). As
the implanted PyMT cells in these tumors did not carry the
Csf1r-driven Cre recombinase and expression of Csf1r is largely
conﬁned to TAMs in such tumors, the knockdown of VEGFA was
restricted to the macrophage lineage, a signiﬁcant source of
VEGFA in the PyMT model (as in cyclophosphamide-treated
LLC1s; ref. 31). Tamoxifen-induced ablation of this TAM-derived
VEGFA (Fig. 5C) caused a signiﬁcant (P<0.05)delay in the growth
Figure 5.
Effect of TAM-derived VEGFA on
relapse of orthotopic MMTV-PyMT
tumors after doxorubicin (DOX)
treatment. A, representative
immunostaining for VEGFA in MRC1þ
TAMs in vascularized (CD31þ) areas
of doxorubicin-treated, Cre, MMTV-
PyMT tumors. This was not seen for
MRC1 TAMs anywhere in the same
tumors (B). C, female Tg(Csf1r-Mer-
iCre-Mer)1jwp;Vegfa
ﬂ/ﬂ) mice bearing
MMTV-PyMT tumors were
administered tamoxifen for 24 hours to
delete VEGFA expression in TAMs
(right panels) after a single injection of
either vehicle alone or doxorubicin. D
and E, growth of tumors treated with
vehicle alone in Creþ and Cre mice
(n ¼ 3–6/group; D) and regrowth of
tumors in Creþ and Cre mice after
treatment with doxorubicin
(n ¼ 3–4/group; E). F, CD31 staining of
vessels in tumors in Cre or Creþ mice
given doxorubicin. Bars, 50 mm.
 , P < 0.05 with respect to tumors at
the same time point in the respective
Cre group.
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of vehicle-treated MMTV-PyMT tumors (Fig. 5D). Furthermore,
relapse of doxorubicin-treated tumors lacking VEGFAþ TAMs
(Creþ) was signiﬁcantly (P < 0.05) slower than that of doxoru-
bicin-treated tumors in VEGFA-expressing (Cre) mice (Fig. 5E).
Thiswas accompaniedby a signiﬁcant (P<0.05) decrease in vessel
area in these tumors (Fig. 5F).
Pharmacologic blockade of CXCR4 prevents perivascular
accumulationofMRC1þVEGFAþTAMsafter chemotherapy and
delays tumor relapse.
The majority of F4/80þMRC1þ TAMs expressed the CXCL12
receptor, CXCR4 in both control and cyclophosphamide-treated
LLC1s (Fig. 6A) and 98%of all CXCR4-expressing cells were TAMs
Figure 6.
Expression of CXCR4 by MRC1þ TAMs
and upregulation of CXCLl2 in LLC1
tumors after cyclophosphamide
(CTX) treatment. A and B,
immunostaining of F4/80 and CXCR4
(A), and the percentage of CXCR4þ
cells coexpressing F4/80 in control
and cyclophosphamide-treated LLCs
(n ¼ 4/group; B). C, immunostaining
of CXCR4 and CD31 in
cyclophosphamide-treated LLCs. D,
ﬂow-cytometric analysis of TAM
expression of CXCR4 and MRC1 in
dispersed cyclophosphamide-
treated LLCs (left), CXCR4 MFI on
MRC1þ vs. MRC1 TAMs (middle;
n ¼ 4–5/group), and tumor levels of
immunodetectable CXCL12 protein in
control and cyclophosphamide-
treated tumors (n ¼ 4/group; right).
E, CXCL12þ cells were perivascular in
cyclophosphamide-treated LLC1s
(left) and exogenous recombinant
human CXCL12 was chemotactic for
MRC1þ/Hi (but not MRC/Lo) TAMs
isolated from LLC1 tumors. Bars,
50 mm. , P < 0.05.
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in cyclophosphamide-treated LLC1 tumors, compared with 78%
in control LLCs (where other cell types were also CXCR4þ
; Fig. 6B). As reported previously (32, 33), LLC1 cells do not
express CXCR4 (Fig. 6A and B).Moreover, less than 1%of CD31þ
blood vessels expressed CXCR4 in cyclophosphamide-treated
tumors (Fig. 6C). MRC1Hi TAMs in both control and cyclophos-
phamide-treated tumors expressed elevated levels of CXCR4
compared with the MRC1Lo TAMs (Fig. 6D).
These changes in CXCR4þ cells after cyclophosphamide were
accompanied by a marked increase in tumor levels of its ligand,
CXCL12, on day 6 (Fig. 6D, far right). These CXCL12þ cells were
CD31 (Fig. 6E, left) and most likely tumor cells and/or ﬁbro-
blasts (34). As a hypoxia-inducible gene (35), itwas not surprising
to ﬁnd CXCL12 more highly expressed in hypoxic than normoxic
areas of control LLC1 tumors. However, after cyclophosphamide,
tumor levels of HIF1 and -2 were markedly reduced in all areas of
tumors (Supplementary Fig. S6A, i and ii), but CXCL12 was
abundant in both hypoxic and normoxic, vascularized areas
(Supplementary Fig. S6B). This suggested CXCL12 upregulation
by factors other than hypoxia in such tumors.
Cyclophosphamide is known to induce oxidative stress (36), a
cellular response known to regulate the expression of CXCL12
(37), so we investigated the expression of a well-deﬁned marker
for oxidative stress, heme oxygenase-1 (HMOX-1) in control
versus cyclophosphamide-treated tumors. Interestingly, this was
found to be upregulated in perivascular, PIMO, CXCL12-rich
areas of tumors after cyclophosphamide treatment but not in
control tumors (Supplementary Fig. S6C, i and ii). Both MRC1þ
TAMs and MRC1 cells expressed HMOX-1 in these vascularized
areas (Supplementary Fig. S6C, iii).
We then investigated whether CXCL12 might recruit and/or
retain CXCR4þMRC1þ TAMs in LLC1 tumors. First, we showed in
an in vitro chemotaxis assay that CXCL12 is selectively chemotactic
for MRC1þ/Hi TAMs isolated from LLC1 tumors (Fig. 6E, right).
Then we administered cyclophosphamide to LLC1-bearing mice
alone or in combination with the CXCR4 antagonist, plerixafor
(AMD3100; Fig 7A). This was feasible as TAMs were the predom-
inant cell type expressing CXCR4 after cyclophosphamide
(Fig. 6B). CXCR4 blockade signiﬁcantly inhibited cyclophospha-
mide-induced accumulation of F4/80þ MRC1þ TAMs in the
PIMO VA (while the numbers in PIMOþ areas of LLC1 tumors
were unchanged, as was F4/80þ MRC1 TAMs in either of these
areas) and delayed tumor relapse (Fig. 7A and B; Supplementary
S5B). At day 10 (when tumors had relapsed in the cyclophos-
phamide alone group), a similar distribution of MRC1þ TAMs
was seen compared with day 6 (the start of the relapse period;
Fig. 7B and C). In addition, tumors administered cyclophos-
phamide þ AMD3100 contained signiﬁcantly (P < 0.05)
shorter CD31þ blood vessels, higher levels of hypoxia, and
fewer BrdUrdþ (proliferating) cells than tumors exposed to
cyclophosphamide with the vehicle for AMD3100 (PBS; Fig.
7D; Supplementary Fig. S5C).
We then examined the effect of CXCR4 blockade on the
distribution of MRC1þ TAMs across PIMO VAs in cyclophos-
phamide-treated tumors. Interestingly, this was found to signif-
icantly (P < 0.05) reduce the number of MRC1þ TAMs in direct
contact with the abluminal surface of CD31þ blood vessels
(standardized by CD31þ vessel area as this differed between
cyclophosphamide þ PBS and cyclophosphamide þ AMD3100
groups), and increase them elsewhere in the PIMOVAs (Fig. 7E).
These data suggest that CXCR4 regulates the direct association of
alternatively activated TAMs with blood vessels in cyclophospha-
mide-treated LLC1s.
A recent study demonstrated a marked rebound in the growth
of pulmonary metastases after treatment with an antibody to
CCL2 (38). This was the result of increased mobilization of
monocytes from the bone marrow after CCL2 inhibition, and
increased blood vessel formation and cancer cell proliferation in
the lungs. We, therefore, investigated the possibility of a similar
rebound effect after CXCR4 inhibition using AMD3100 as this
could disrupt the bone marrow niche. When we extended the
length of the AMD3100 experiment, primary LLC1 tumors
relapsed eventually, but not at an accelerated rate, and mice
receiving cyclophosphamide þ AMD3100 showed increased sur-
vival compared with those in the cyclophosphamide alone group
(or controls). Importantly, there was also no rebound in pulmo-
nary metastases (Supplementary Fig. S8).
Discussion
Our studies show that M2-skewed TAMs (MRC1þTIE2þ-
CXCR4HiVEGFAþ) selectively accumulate in vascularized, well-
oxygenated areas of LLC1 tumors after treatment with cyclophos-
phamide. A similar increase in such vessel-associated, M2-skewed
TAMswas also seen in orthotopic 4T1 andMMTV-PyMT implants
after treatment with paclitaxel and doxorubicin, respectively, and
in human breast carcinomas after neoadjuvant treatment with
paclitaxel. This perivascular accumulation was found to be
CXCR4-dependent, especially the increased, direct contact of this
TAM subset with the abluminal surface of blood vessels in
chemotherapy-treated tumors. When this was disrupted using a
CXCR4 inhibitor, tumor revascularization and regrowth after
chemotherapy were markedly impaired. We also show, using an
inducible, macrophage-speciﬁc, gene knockdown model that
VEGFA expressed by such MRC1þ TAMs mediates, in part, their
ability to promote tumor relapse after therapy. Consistent with
this, genetic deletion of HIF signaling in TAMs in hypoxic tumor
areas had no effect on this rescue.
The mobilization and accumulation in tumors, of such
BMDCs as myelomonocytic cells, MDSCs, endothelial progen-
itor cells (EPC) and macrophages after various forms of anti-
cancer therapy are now well established (13–19, 39, 40).
However, our data show that M2-skewed TAMs represent a
signiﬁcant proportion of such BMDCs in tumors after chemo-
therapy, and is not accompanied by TAM proliferation or
increased numbers of stem/progenitor cells. These data suggest
that increased recruitment of circulating monocytes precedes
the accumulation of such M2 TAMs in tumors after chemo-
therapy. It remains to be seen whether monocytes are already
M2-skewed upon arrival in treated tumors and/or activated by
factors produced in the perivascular niche. Of note, the recruit-
ment, activation, and perivascular retention of these cells does
not appear to be just an acute response to chemotherapy-
induced tumor damage, as increased numbers of perivascular
M2 TAMs persisted throughout the relapse phase.
Our observations suggest that the accumulation of MRC1þ
VEGFAþ TAMs on and around the tumor vasculature plays an
important part in tumor revascularization and relapse after che-
motherapy. Furthermore, this was accompanied by a marked
change in the pattern of CXCL12 expression in tumors. Although
CXCL12 was mainly conﬁned to hypoxic areas of control tumors,
it was upregulated in vascularized, well-oxygenated areas after
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chemotherapy. This correlated with an increase in the expression
of the enzyme, HMOX-1, a marker of oxidative stress, in such
perivascular areas. Cytotoxic agents such as cyclophosphamide
induce oxidative stress in tumors (41), which activates cellular
expression of HMOX-1. This, in turn, generates carbonmonoxide
from the breakdown of heme, a gas known to upregulate both
CXCL12 and VEGFA in neighboring cells (37). Interestingly,
HMOX-1 also regulates expression of MRC1 by macrophages
(42). So, chemotherapy induction of this stress pathway in
perivascular areas could both retain TAMs via local CXCL12
induction, and upregulate their expression of VEGFA and MRC1.
Interestingly, the CXCL12-induced retention of myeloid cells
around the vasculature is also essential to the process of neovas-
cularization in nonmalignant tissues (43).
Other factors may also contribute to the retention of MRC1þ
TAMs. Our observation that MRC1þ TAMs expressed elevated
TIE2 suggests that ANGPT2 expressed by the tumor endothe-
lium (44) might also be involved. Indeed, ANGPT2 has an
established role in retaining vascular modulatory myeloid
cells in proximity to the vasculature in progressing mouse
tumors (26).
In untreated mouse tumors, perivascular M2-skewed TAMs
have an established vascular modulatory role and facilitate
tumor growth and progression (26). Our observation that
chemotherapy induces the accumulation of MRC1þVEGFAþ
TAMs around tumor blood vessels strongly infers a proangio-
genic role for these cells. This is supported by our ﬁnding that
pharmacologic inhibition of their chemotherapy-induced accu-
mulation resulted in reduced subsequent tumor revasculariza-
tion. Furthermore, in doxorubicin-treated, MMTV-PyMT tumor
implants VEGFA was found to be expressed predominantly by
MRC1þ TAMs, consistent with our previous ﬁnding that TAMs
Figure 7.
Effect of the CXCR4 inhibitor
AMD3100 on LLC1 relapse after
cyclophosphamide (CTX): role of
perivascular MRC1þCXCR4Hi TAMs.
A, regrowth of tumors in mice treated
with PBS, PBS þ AMD3100,
cyclophosphamide þ PBS, or
cyclophosphamide þ AMD3100 (n ¼
5–9/group). B and C, F4/80þMRC1þ
TAMs in the PIMO VA and hypoxic
(PIMOþ) areas of cyclophosphamide þ
PBS or cyclophosphamide þ AMD3100
treated tumors (n ¼ 4–6/group) at day
6 (B) and day 10 (n ¼ 7–9/group; C). D,
total CD31þ vessel area in tumors
treated with cyclophosphamide þ PBS
and cyclophosphamideþ AMD3100 (at
day 6 in A). E, MRC1þ TAMs in direct
contact (abluminal) or not in contact
with (non-abluminal) with CD31þ
endothelial cells in PIMO VA areas of
either cyclophosphamide þ PBS or
cyclophosphamide þ AMD3100-
treated LLCs (normalized to total
CD31þ area in each ﬁeld).  , P < 0.05.
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are a major source of VEGFA in MMTV-PyMT tumors (31). The
selective ablation of VEGFA in MRC1þ TAMs resulted in
delayed tumor relapse, post-therapy. However, PyMT tumors
still relapsed, albeit at a reduced rate, in the absence of TAM-
derived VEGFA, indicating that other TAM-derived factors may
also contribute to tumor relapse and/or the possible induction
of resistance mechanisms in tumors to VEGFA knockout. The
presence of the latter has been demonstrated in tumors after
anti-VEGFA therapy and shown to include increased expression
of such alternative proangiogenic mediators as FGF2 (45),
ANGPT2 (46), or PlGF (47) and the recruitment of tumor-
promoting, CD11bþ Gr1þ myeloid cells (48).
Recently, the Condeelis group has used intravital imaging to
characterize a distinct subset of perivascular TAMs in untreated
mouse tumors thatmake contact with endothelial cells and tumor
cells expressing high levels of Mena (a protein that enhances their
motility), and directly stimulate tumor cell intravasation (49).
These cell trios have been termed "tumor microenvironments of
metastasis" (TMEM). It is possible that some of the perivascular
MRC1þ M2-skewed TAMs accumulating around tumor blood
vessels after chemotherapy form TMEMs and promote metastasis
as well as relapse, a dangerous combination in patients with
inoperable tumors.
The effect of CXCR4 blockade on tumor relapse after chemo-
therapy in our study suggests that CXCR4 inhibitors might be
successfully combined with chemotherapy. This combination
could extend relapse-free survival in patients with inoperable
tumors, although our data suggests that multiple rounds of the
inhibitor would have to be administered to maintain a suppres-
sive effect on relapse. Such sustained use of a CXCR4 antagonist
after chemotherapy could conceivably disrupt the marrow niche.
However, this is unlikely to lead to clinical problems as a recent,
ﬁrst-in-human clinical trial has shown that repeated daily injec-
tions of the CXCR4 antagonist, LY2510924 over a number of
consecutive, 28-day cycles was well tolerated in advanced cancer
patients (50).
Taken together, our data suggest that the selective targeting of
relapse-promoting, perivascular TAMs could delay the relapse of
both primary and metastatic tumors in patients after chemother-
apy, thereby extending their relapse-free survival.
Disclosure of Potential Conﬂicts of Interest
No potential conﬂicts of interest were disclosed.
Authors' Contributions
Conception and design: R. Hughes, B.-Z. Qian, M. Muthana, J.W. Pollard,
C.E. Lewis
Development ofmethodology:R.Hughes, B.-Z.Qian, C. Addison, J.W. Pollard,
C.E. Lewis
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): R. Hughes, B.-Z. Qian, C. Rowan, I. Keklikoglou,
O.C. Olson, S. Tazzyman, C. Addison, M. Clemons, A.M. Gonzalez-Angulo,
J.A Joyce, M. De Palma, J.W. Pollard, C.E. Lewis
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): R. Hughes, B.-Z. Qian, C. Rowan, S. Tazzyman,
S. Danson, J.W. Pollard, C.E. Lewis
Writing, review, and/or revision of the manuscript: R. Hughes, B.-Z. Qian,
S. Danson, C. Addison, A.M. Gonzalez-Angulo, J.A Joyce, M. De Palma,
J.W. Pollard, C.E. Lewis
Administrative, technical, or material support (i.e., reporting or organizing
data, constructing databases): R. Hughes, M. Muthana
Study supervision: R. Hughes, M. Muthana, J.W. Pollard, C.E. Lewis
Grant Support
This work was supportedmainly by a Cancer Research UK grant (C.E. Lewis),
the grant support of the Swiss Cancer League (M. De Palma), Breast Cancer
Research Foundation (O.C. Olson and J.A Joyce), a Chancellor's Fellowship
from the University of Edinburgh (B.-Z. Qian), and TheWellcome Trust (Senior
Investigator Award; J.W. Pollard).
The costs of publication of this articlewere defrayed inpart by the payment of
page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received December 10, 2014; revised July 3, 2015; accepted July 10, 2015;
published OnlineFirst August 12, 2015.
References
1. Savir G, Huber KE, Saif MW. Locally advanced pancreatic cancer. Looking
beyond traditional chemotherapy and radiation. JOP 2013;14:337–9.
2. Strom HH, Bremnes RM, Sundstrom SH, Helbekkmo N, Aasebo U. Poor
prognosis patients with inoperable locally advanced NSCLC and large
tumors beneﬁt frompalliative chemoradiotherapy: a subset analysis froma
randomized clinical phase III trial. J Thorac Oncol 2014;9:825–33.
3. Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M. Elusive
identities and overlapping phenotypes of proangiogenic myeloid cells in
tumors. Am J Pathol 2010;176:1564–76.
4. Noy R, Pollard JW. Tumor-Associated Macrophages: From Mechanisms to
Therapy. Immunity 2014;41:49–61.
5. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression
and metastasis. Cell 2010;141:39–51.
6. Movahedi K, Laoui D, Gysemans C, BaetenM, Stange G, Van den Bossche J,
et al. Different tumor microenvironments contain functionally distinct
subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res
2010;70:5728–39.
7. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors
of angiogenesis and tumor progression. Biochimica et biophysica acta
2009;1796:11–8.
8. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during
tumor progression: regulation by distinct molecular mechanisms. J Immu-
nol 2008;180:2011–7.
9. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguish-
ing gene signature shared by tumor-inﬁltrating Tie2-expressingmonocytes,
blood "resident" monocytes, and embryonic macrophages suggests
common functions and developmental relationships. Blood 2009;114:
901–14.
10. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M,
et al. Tie2 identiﬁes a hematopoietic lineage of proangiogenic monocytes
required for tumor vessel formation and a mesenchymal population of
pericyte progenitors. Cancer Cell 2005;8:211–26.
11. Daenen LG, Houthuijzen JM, Cirkel GA, Roodhart JM, Shaked Y, Voest EE.
Treatment-induced host-mediated mechanisms reducing the efﬁcacy of
antitumor therapies. Oncogene 2014;33:1341–7.
12. De Palma M, Lewis CE. Macrophage regulation of tumor responses to
anticancer therapies. Cancer Cell 2013;23:277–86.
13. DeNardoDG, BrennanDJ, Rexhepaj E, Ruffell B, Shiao SL,Madden SF, et al.
Leukocyte complexity predicts breast cancer survival and functionally
regulates response to chemotherapy. Cancer Discov 2011;1:54–67.
14. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, et al.
Imaging tumor-stroma interactions during chemotherapy reveals contri-
butions of the microenvironment to resistance. Cancer Cell 2012;21:
488–503.
15. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al.
Macrophages and cathepsin proteases blunt chemotherapeutic response
in breast cancer. Genes Dev 2011;25:2465–79.
16. AhnGO, TsengD, Liao CH,DorieMJ, Czechowicz A, Brown JM. Inhibition
of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reduc-
ing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010;107:8363–8.
Hughes et al.
Cancer Res; 75(17) September 1, 2015 Cancer Research3490
on September 1, 2015. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 12, 2015; DOI: 10.1158/0008-5472.CAN-14-3587 
17. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM.
Inhibition of vasculogenesis, but not angiogenesis, prevents the recur-
rence of glioblastoma after irradiation in mice. J Clin Invest 2010;
120:694–705.
18. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG.
Recruitment of myeloid but not endothelial precursor cells facilitates
tumor regrowth after local irradiation. Cancer Res 2010;70:5679–85.
19. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-
expressing macrophages limit the therapeutic efﬁcacy of the vascular-
disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011;
121:1969–73.
20. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage
plasticity and polarization in tissue repair and remodelling. J Pathol
2013;229:176–85.
21. Browder T, Butterﬁeld CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al.
Antiangiogenic scheduling of chemotherapy improves efﬁcacy against
experimental drug-resistant cancer. Cancer Res 2000;60:1878–86.
22. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S,
et al. B cells regulate macrophage phenotype and response to chemother-
apy in squamous carcinomas. Cancer Cell 2014;25:809–21.
23. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2
recruits inﬂammatory monocytes to facilitate breast-tumour metastasis.
Nature 2011;475:222–5.
24. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct
visualization of macrophage-assisted tumor cell intravasation in mamma-
ry tumors. Cancer Res 2007;67:2649–56.
25. Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, et al.
Acquisition of metastatic tissue from patients with bone metastases from
breast cancer. Breast Cancer Res Treat 2011;129:761–5.
26. Mazzieri R, Pucci F,MoiD, Zonari E, Ranghetti A, Berti A, et al. Targeting the
ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing
angiogenesis and disabling rebounds of proangiogenic myeloid cells.
Cancer Cell 2011;19:512–26.
27. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg
JI, et al. Deletion of vascular endothelial growth factor in myeloid cells
accelerates tumorigenesis. Nature 2008;456:814–8.
28. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel
chemoimmunomodulating property of docetaxel: suppression of mye-
loid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;
16:4583–94.
29. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruit-
ment of macrophages into hypoxic areas of tumors and other ischemic
tissues. Blood 2004;104:2224–34.
30. Fang HY, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, et al.
Hypoxia-inducible factors 1 and 2 are important transcriptional effec-
tors in primary macrophages experiencing hypoxia. Blood 2009;114:
844–59.
31. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages
regulate the angiogenic switch in a mouse model of breast cancer. Cancer
Res 2006;66:11238–46.
32. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A,
et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is
expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A
2007;104:15735–40.
33. Weiss ID, JacobsonO, Kiesewetter DO, Jacobus JP, Szajek LP, Chen X, et al.
Positron emission tomography imaging of tumors expressing the human
chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100. Mol
Imaging Biol 2012;14:106–14.
34. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al.
Targeting CXCL12 from FAP-expressing carcinoma-associated ﬁbroblasts
synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl
Acad Sci U S A 2013;110:20212–7.
35. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-
induced production of stromal cell-derived factor 1 (CXCL12) and vascular
endothelial growth factor by synovial ﬁbroblasts. Arthritis Rheum 2002;
46:2587–97.
36. Li L, Jiang L, Geng C, Cao J, Zhong L. The role of oxidative stress in
acrolein-induced DNA damage in HepG2 cells. Free Radic Res 2008;
42:354–61.
37. Lin HH, Chen YH, Chang PF, Lee YT, Yet SF, Chau LY. Heme oxygenase-1
promotes neovascularization in ischemic heart by coinduction of VEGF
and SDF-1. J Mol Cell Cardiol 2008;45:44–55.
38. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al.
Cessation of CCL2 inhibition accelerates breast cancer metastasis by
promoting angiogenesis. Nature 2014;515:130–3.
39. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ,
Montero AJ. Increased circulating myeloid-derived suppressor cells corre-
late with clinical cancer stage, metastatic tumor burden, and doxorubicin-
cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;
58:49–59.
40. Shaked Y,Henke E, Roodhart JM,Mancuso P, LangenbergMH,ColleoniM,
et al. Rapid chemotherapy-induced acute endothelial progenitor cell
mobilization: implications for antiangiogenic drugs as chemosensitizing
agents. Cancer Cell 2008;14:263–73.
41. Chen Y, Jungsuwadee P, Vore M, Butterﬁeld DA, StClair DK. Collateral
damage in cancer chemotherapy: oxidative stress in nontargeted tissues.
Mol Interv 2007;7:147–56.
42. Tu TH, Joe Y, Choi HS, Chung HT, Yu R. Induction of heme oxygenase-1
with hemin reduces obesity-induced adipose tissue inﬂammation via
adipose macrophage phenotype switching. Mediators Inﬂamm 2014;
2014:290708.
43. GrunewaldM, Avraham I,Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-
induced adult neovascularization: recruitment, retention, and role of
accessory cells. Cell 2006;124:175–89.
44. Stratmann A, Risau W, Plate KH. Cell type-speciﬁc expression of angio-
poietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis.
Am J Pathol 1998;153:1459–66.
45. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by
evasion of antiangiogenic targeting of VEGF signaling in late-stage pan-
creatic islet tumors. Cancer Cell 2005;8:299–309.
46. Rigamonti N, Kadioglu E, Keklikoglou I, Rmili CW, LeowCC,De PalmaM.
Role of angiopoietin-2 in adaptive tumor resistance to VEGF signalling
blockade. Cell Rep 2014;8:696–706
47. FischerC, JonckxB,MazzoneM,Zacchigna S, Loges S, Pattarini L, et al. Anti-
PlGF inhibits growthof VEGF(R)-inhibitor-resistant tumorswithout affect-
ing healthy vessels. Cell 2007;131:463–75.
48. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor
refractoriness to anti-VEGF treatment is mediated by CD11bþGr1þmye-
loid cells. Nat Biotechnol 2007;25:911–20.
49. Roussos ET, Goswami S, Balsamo M, Wang Y, Stobezki R, Adler E, et al.
Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in
breast cancer cell cohesion and association with TMEM. Clin Exp Metas-
tasis 2011;28:515–27.
50. GalskyMD,VogelzangNJ,Conkling P, RaddadE, Polzer J, RobersonS, et al.
A Phase I Trial of LY2510924, a CXCR4 peptide antagonist, in patients with
advanced cancer. Clin Cancer Res 2014;20:3581–8.
www.aacrjournals.org Cancer Res; 75(17) September 1, 2015 3491
Macrophages and Tumor Relapse
on September 1, 2015. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 12, 2015; DOI: 10.1158/0008-5472.CAN-14-3587 
2015;75:3479-3491. Published OnlineFirst August 12, 2015.Cancer Res 
  
Russell Hughes, Bin-Zhi Qian, Charlotte Rowan, et al. 
  
Chemotherapy
Perivascular M2 Macrophages Stimulate Tumor Relapse after
  
Updated version
  
 10.1158/0008-5472.CAN-14-3587doi:
Access the most recent version of this article at:
  
  
  
  
  
Cited articles
  
 http://cancerres.aacrjournals.org/content/75/17/3479.full.html#ref-list-1
This article cites 50 articles, 16 of which you can access for free at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
.permissions@aacr.org
To request permission to re-use all or part of this article, contact the AACR Publications Department at
on September 1, 2015. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 12, 2015; DOI: 10.1158/0008-5472.CAN-14-3587 
